Neurol. praxi. 2020;21(1):60-62 | DOI: 10.36290/neu.2020.027

Treatment of multiple sclerosis with first-line therapy and prenancy

MUDr. Mgr. Matouš Rous, MUDr. Zuzana Rous, Ph.D.
Neurologická klinika FN a LF UP Olomouc

Teriflunomide is a disease modyfing drug for treatment in multiple sclerosis as one of the options for first-line therapy. It has teratogenic and embyotoxic potential according to animal studies. The data on pregnancy use in women are limited and its use in pregnancy is contraindicated. However, there are cases where women have taken teriflunomide during conception and pregnancy.

Keywords: multiple sclerosis, teriflunomide, pregnancy.

Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rous M, Rous Z. Treatment of multiple sclerosis with first-line therapy and prenancy. Neurol. praxi. 2020;21(1):60-62. doi: 10.36290/neu.2020.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int. 2016; 2016: 1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18. Go to original source... Go to PubMed...
    2. Andersen JB, Moberg JY, Spelman T, Magyari M. Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study. Front Immunol. 2018; 9: 2706. doi: 10.3389/fimmu.2018.02706. eCollection 2018. Go to original source... Go to PubMed...
    3. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014; 74(6): 659-74. doi: 10.1007/s40265-014-0212-x. Go to original source...
    4. Cofavreux C. OĆonnor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(3): 247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Go to original source...
    5. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016; 5: 97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10. Go to original source... Go to PubMed...
    6. Davenport L, Edling A, Finn P, Truffinet P, Cavalier S. Teriflunomide mechanism of action: linking species' sensitivities to pregnancy outcomes. Poster (P1033) presented at ECTRIMS 2015, 7-10 October, Barcelona, Spain. References from that poster.
    7. Davenport L, Czich A, Turpault S. Teriflunomide: No Effects on Sperm DNA. Poster (P1187) presented at ECTRIMS 2013, 2-5 October, Copenhagen, Denmark. References from that presentation.
    8. Dufek M. Roztroušená skleróza - EDSS (Expanded Disability Status Scale), tzv. Kurtzkeho škála. Neurol. praxi 2011: 12.
    9. Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS; Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oralteriflunomide in relapsing multiple sclerosis. Mult Scler. 2012; 18(11): 1625-1632. doi: 10.1177/1352458512450354. Epub 2012 Jun 21. Go to original source... Go to PubMed...
    10. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(10): 977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2. Go to original source...
    11. Ullrich A, Knecht W, Fries M, Löffler M. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Eur J Biochem. 2001; 268(6): 1861-8. Go to original source...
    12. Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler. 2019; 10: 1352458519843055. doi: 10.1177/1352458519843055. Go to original source...
    13. (SPC): https://www.ema.europa.eu/en/documents/product - information/aubagio-epar-product-information_cs.pdf.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.